Consenso Argentino de toxoplasmosis congénita 2020 / Argentine Consensus of congenital toxoplasmosis

Resumen La transmisión vertical de la infección por Toxoplasma gondii ocurre cuando la madre se infecta por primera vez en el transcurso del embarazo. El diagnóstico de la infección materna y la del re cién nacido se logra con el conjunto de pruebas serológicas, hallazgos clínicos y ecográficos. El reconocimiento temprano de la infección materna permite un tratamiento que reduce la tasa de transmisión y el riesgo de daño en el producto de la concepción. El objetivo de este consenso de expertos fue revisar la literatura científica para actualizar las recomendaciones de práctica clínica respecto de la prevención, el diagnóstico y el tratamiento de la toxoplasmosis congénita en nuestro país.

Abstract Mother-to-child transmission in Toxoplasma gondii infection occurs only when the infection is acquired for the first time during pregnancy. Diag nosis of maternal infection and the newborn is achieved by a combination of serological tests, clinical features and ultrasound images. An early diagnosis of maternal infection allows treatment that offers a reduction both in transmission rate and risk of congenital damage. The aim of this expert consensus was to review the scientific literature which would enable an update of the clinical practice guideline of prevention, diagnosis and treatment of congenital toxoplasmosis in our country.

Condução da toxoplasmose gestacional / Management of gestational toxoplasmosis

A toxoplasmose é uma doença proveniente do Toxoplasma gondii, um protozoário que tem os felinos como seu hospedeiro definitivo e os mamíferos e aves como seu hospedeiro intermediário. Tem um curso benigno e autolimitado quando acomete um indivíduo imunocompetente, no entanto a infecção durante a gestação acarreta até 50% de chance de toxoplasmose congênita, podendo causar danos severos ao feto. A virulência dos genótipos encontrados nas Américas Central e do Sul é a mais alta, comparada a Europa e América do Norte, tendo a doença um comportamento mais agressivo. Os estudos relatam a diminuição da infecção fetal em até 60% com o uso da espiramicina, usada ainda na profilaxia. Este artigo discute sobre a triagem materna pré-natal e sua necessidade, a profilaxia e o tratamento da infecção fetal ainda intraútero, com o objetivo de diminuir a transmissão vertical e as sequelas neonatais com suas implicações ao longo da vida.(AU)

Toxoplasmosis it is a disease originating from Toxoplasma gondii, a protozoan that has felines at as ultimate host and mammals and birds at as intermediate host. Has a benign and self-limiting course when affects immunocompetent individual, however, infection during pregnancy leads 50% chance of congenital toxoplasmosis and can cause severe damage to the fetus. The virulence of genotypes found in Central and South America is the highest compared to Europe and North America, having the disease a more aggressive behavior. Studies report a reduction in fetal infection 60% with the use spiramycin still used for prophylaxis. This article discusses prenatal maternal screening, prophylaxis and treatment of fetal infection still in utero with the objective of decreasing vertical transmission and neonatal sequelae with their lifelong implications.(AU)

Follow-up of toxoplasmosis during pregnancy: ten-year experience in a University hospital in southern Brazil / Acompanhamento da toxoplasmose durante a gravidez: uma década de experiência em um hospital universitário no Sul do Brasil

Abstract Objective To describe a population of pregnant women diagnosed with toxoplasmosis and their respective newborns, describing the hospital protocol for treatment and follow-up. Methods Retrospective cohort of pregnant women with acute toxoplasmosis infection and risk of transplacental transmission who were sent to the Fetal Medicine Group of Hospital de Clínicas de Porto Alegre (HCPA) between - January 1, 2006 and December 31, 2016. All patients with confirmed disease were included. The diagnostic protocol and treatment were applied; a polymerase chain reaction (PCR) analysis of the amniotic fluid was used to diagnose toxoplasmosis and determine the treatment. The newborns were followed up at the pediatric outpatient clinic specializing in congenital infection. The patients who were not followed up or were not born in the HCPA were excluded. Results A total of 65 patients were confirmed to have gestational toxoplasmosis; 40 performed amniocentesis, and 6 (15%) were identified as having positive PCR in the amniotic fluid. In five of those cases, this result associated with the gestational age defined the triple therapy during pregnancy, and in one case, it defined the monotherapy (advanced gestational age). A total of 4 of these newborns were treated from birth with triple therapy for 10months, 1 was not treated (due to maternal refusal), and 1 progressed to death within the first 54 hours of life due to complications of congenital toxoplasmosis. Of the 34 remaining cases with a negative PCR, 33 were treated with monotherapy and 1 was treated with triple therapy (ultrasound findings); of these children, 9 (26.5%) presented negative immunoglobulin G (IgG), 24 (70.6%) presented positive IgG (but none presented positive immunoglobulin M [IgM]), and 1 (2,9%) presented alterations compatible with congenital disease and started treatment with the triple therapy soon after birth. Out of the total sample of 60 patients, among the 25 who did not perform amniotic fluid PCR, 5 were treated with triple therapy (ultrasound findings/prior treatment) and 20 patients were submitted to monotherapy; only two newborns underwent treatment for congenital toxoplasmosis. Among the 65 cases of gestational toxoplasmosis, 6 (9,2%) children had a diagnosis of congenital toxoplasmosis, and 2 patients with triple therapy felt severe adverse effects of the medications. Conclusions The present study suggests that research on PCR screening of the amniotic fluid may be useful to identify patients with a higher potential for fetal complications, who may benefit from the poly-antimicrobial treatment. Patients with negative PCR results must continue to prevent fetal infection with monotherapy, without risk of fetal or maternal impairment.

Resumo Objetivo Descrever uma população de pacientes diagnosticadas com toxoplasmose na gestação e seus respectivos recém-nascidos, relatando o protocolo do hospital durante o tratamento e seguimento. Métodos Coorte retrospectiva de gestantes com infecção aguda por toxoplasmose e risco de transmissão transplacentária, encaminhadas para acompanhamento pelo Grupo deMedicina Fetal doHospital de Clínicas de Porto Alegre (HCPA) entre 1o de janeiro de 2006 e 31 de dezembro de 2016. Todas as pacientes comdoença confirmada foram incluídas. O protocolo de diagnóstico e tratamento foi aplicado; uma análise da reação em cadeia da polimerase (RCP) no líquido amniótico foi utilizada para diagnosticar a toxoplasmose e determinar o tratamento. Os recém-nascidos foram acompanhados no ambulatório de pediatria especializadoeminfecções congênitas. Pacientes que não foramseguidas ou cujo parto não foi feito no hospital foram excluídas. Resultados A toxoplasmose gestacional foi confirmada em 65 pacientes; 40 realizaram amniocentese, e 6 (15%) foram identificadas com RCP positiva no líquido amniótico. Este resultado associado à idade gestacional definiu a terapia tríplice durante a gestação em 5 casos, e a monoterapia em 1 caso (por idade gestacional avançada). Quatro destas crianças foram tratadas desde o nascimento com terapia tríplice por 12 meses, 1 não foi tratada (por recusa materna), e 1 evoluiu com óbito dentro das primeiras 54 horas de vida devido a complicações da toxoplasmose congênita. Dos 34 casos remanescentes com RCP negativa, 33 foram tratados com monoterapia, e 1 foi tratado com terapia tríplice (por achados ultrassonográficos); destes recém-nascidos, 9 (26,5%) tiveram imunoglobulina G (IgG) negativa, 24 (70,6%) tiveram IgG positiva, mas nenhum apresentou imunoglobulina M (IgM) positiva, e 1 (2,9%) apresentou alterações compatíveis comdoença congênita e iniciou a terapia tríplice logo após o nascimento. Entre as 25 pacientes que não fizeram RCP no líquido amniótico, 5 foram tratadas com terapia tríplice (por achados ultrassonográficos/ tratamento prévio) e 20 receberam monoterapia; somente 2 recém-nascidos receberam tratamento para toxoplasmose congênita. Entre os 65 casos de toxoplasmose gestacional, 6 (9,2%) recém-nascidos tiveram o diagnóstico de toxoplasmose congênita. Um total de 2 pacientes submetidas à terapia tríplice apresentaram efeitos adversos severos das medicações utilizadas. Conclusão Este estudo sugere que a triagem da RCP para toxoplasmose do líquido amniótico pode ser útil no rastreamento de pacientes com maior potencial para complicações fetais, que podem se beneficiar do tratamento poli antimicrobiano. Pacientes com RCP negativa devem continuar a prevenir a infecção fetal com monoterapia, sem risco de comprometimento fetal ou materno.

Congenital toxoplasmosis: the challenge of early diagnosis of a complex and neglected disease

Abstract The objective of this study was to report a case of congenital toxoplasmosis that illustrates the difficulties in diagnosing this disease. The case highlights the lack of prophylactic guidelines and shortcomings in the gestational screening process. It demonstrates the peculiarities of the non-specific clinical picture of the infection acquired during pregnancy and identifies the challenges of ophthalmological and high-sensitivity exams in newborns that are crucial for an early diagnosis. These factors contribute to a delay in early treatment of both the mother and the newborn. The lack of skill and expertise of clinical physicians to manage the disease is also addressed.

Efecto del tratamiento prenatal con espiramicina en la frecuencia de retinocoroiditis por toxoplasmosis congénita en una cohorte colombiana / Effect of antenatal spiramycin treatment on the frequency of retinochoroiditis due to congenital toxoplasmosis in a Colombian cohort

Resumen Introducción. La toxoplasmosis de la gestación es frecuente y grave. Hasta ahora no hay consenso sobre la utilidad del tratamiento para prevenir complicaciones oculares en el neonato. En la actualidad, uno de los medicamentos utilizados en las madres diagnosticadas es la espiramicina oral. Infortunadamente, en algunas mujeres gestantes no se hace el diagnóstico prenatal y, por esta u otras razones, no reciben el tratamiento. Objetivo. Describir la relación entre el tratamiento con espiramicina durante el embarazo en madres con toxoplasmosis de la gestación y la presentación de toxoplasmosis ocular en los recién nacidos. Materiales y métodos. Se llevó a cabo un estudio observacional descriptivo de serie de casos. Se evaluó una serie prospectiva de pacientes con toxoplasmosis de la gestación durante tres años de seguimiento en el Servicio de Retinología de la Clínica Universitaria Bolivariana de Medellín. Resultados. Se registraron 23 madres con diagnóstico de toxoplasmosis de la gestación. Quince de ellas (65 %) recibieron durante la gestación tratamiento con espiramicina en dosis de 3 g al día; uno de los neonatos (6,6 %) presentó toxoplasmosis ocular. De las ocho (35 %) pacientes que no recibieron tratamiento, cinco (62,5 %) tuvieron hijos con compromiso ocular por toxoplasma. La razón de momios (odds ratio, OR) del efecto protector contra dicho compromiso en los pacientes cuyas madres recibieron tratamiento fue de 0,04 (IC95% 0,00-0,67), con valor de p menor de 0,01 en la prueba exacta de Fisher. Solo se evidenció compromiso del sistema nervioso central por toxoplasmosis mediante las imágenes de tomografía o ecografía cerebral en dos (14 %) pacientes de las 14 en quienes se hicieron estos estudios. Los dos pacientes presentaron, además, compromiso ocular; ambos fueron diagnosticados en el momento del nacimiento y sus madres no habían recibido tratamiento prenatal. Conclusiones. Estos resultados evidencian que el tratamiento con espiramicina durante el embarazo en la toxoplasmosis de la gestación redujo en 96 % (IC95% 33-100 %) el riesgo relativo de presentar la enfermedad en el recién nacido.

Abstrat Introduction: Gestational toxoplasmosis is frequent and severe. There is still debate about the benefits of treatment against ocular manifestations in the newborn. Spiramycin treatment is used for this purpose, unfortunately prenatal diagnosis is sometimes delayed and pregnant women are not treated. Objective: To describe the relationship between treatment with spiramycin during pregnancy in mothers with gestational toxoplasmosis and development of ocular toxoplasmosis in newborns. Materials and methods: We conducted a descriptive study of a case series. We evaluated a prospective cohort of patients diagnosed with gestational toxoplasmosis during three years at the Retinology Service at the Clínica Universitaria Bolivariana in Medellín. Results: Gestational toxoplasmosis was found in 23 mothers; 15 (65%) were treated during pregnancy with 3 g per day of spiramycin, eight (35%) patients were untreated. In the treated group just one newborn developed ocular toxoplasmosis (6.6%), in contrast with five (62.5%) of the eight patients who did not receive treatment. These results suggest that pregnancy treatment reduces the relative risk of ocular toxoplasmosis in the newborn by 96% (95% CI: 33 - 100%). Only two (14%) of the patients who were evaluated, had nervous system involvement related to toxoplasmosis in CT scan or cerebral ultrasound. These two patients also developed ocular pathology and were diagnosed at the time of birth, so they did not received antenatal treatment. Conclusions: A protective effect was found against the ocular involvement in patients whose mother received treatment with spiramycin (OR=0.04;95% CI: 0.00-0.67), p<0.01 (Fisher's Exact Test).

Submacular hemorrhage secondary to congenital toxoplasmosis / Hemorragia submacular secundária à toxoplasmose congênita

We report the case of a patient with congenital toxoplasmosis and submacular hemorrhage caused by a neovascular membrane who underwent an intravitreal injection of C3F8 and bevacizumab, and had a good visual recovery.

Relatamos o caso de uma paciente com toxoplasmose congênita e hemorragia submacular por uma membrana neovascular submetida à injeção intravítrea de C3F8 e bevacizumabe, com boa recuperação visual.

Profile of pregnant women and children treated at a reference center for congenital toxoplasmosis in the northern state of Minas Gerais, Brazil / Perfil de mulheres grávidas e crianças atendidas em um centro de referência para toxoplasmose congênita no norte do estado de Minas Gerais, Brasil

INTRODUCTION: To describe the clinical and epidemiological profile of pregnant women and children treated at a reference outpatient clinic for congenital toxoplasmosis. METHODS: Pregnant women potentially exposed to Toxoplasma gondii were observed. Diagnoses were made using serologic tests compatible with acute toxoplasmosis. Children presenting with: Toxoplasma-specific antibodies (IgM or IgA or ascending IgG titers higher than maternal titers in the first 3 months of life) coupled with toxoplasmosis symptoms; intracranial calcifications (by transfontanelar ultrasound or cephalic segment tomography); or retinochoroiditis (by fundoscopy examination) in the first 8 months of life were also included in the study. RESULTS: Fifty-eight mother-child pairs were observed (mean age of the mothers was 22.1 years). Most patients lived in urban areas (86.2 percent) and had attended less than 8 years of school (51.7 percent). Diagnosis was made after birth in 19 (32.8 percent) children. Thirty-four (58.6 percent) women received some type of treatment during pregnancy. Most (72.4 percent) of the children did not present with clinical alterations at birth. The main findings were ophthalmological: 20 (34.5 percent) children with retinochoroiditis, 17 (29.3 percent) with strabismus, and 7 (12.1 percent) with nystagmus. Of the children with retinochoroiditis, 9 presented with subnormal vision. Ten (32.3 percent) out of 31 children presented with intracranial calcifications by cephalic segment congenital toxoplasmosis, and 9 (42.9 percent) children presented with delayed psychomotor development. CONCLUSIONS: Our results highlight a critical situation. Protocols for follow-up of pregnant women and their children must be created to improve medical care and minimize sequelae.

INTRODUÇÃO: Descrever o perfil clínico e epidemiológico de gestantes e crianças atendidas em um centro de referência para toxoplasmose congênita. MÉTODOS: Gestantes potencialmente expostas ao Toxoplasma gondii foram estudadas. Os diagnósticos foram feitos através de testes sorológicos compatíveis com toxoplasmose aguda. Crianças que apresentaram anticorpos específicos (IgM e IgA ou títulos ascendentes de IgG, superiores aos títulos maternos nos primeiros três meses de vida), juntamente com os sintomas da toxoplasmose, calcificações intracranianas (ultrassom transfontanela ou tomografia do segmento cefálico), ou retinocoroidite (fundoscopia) nos primeiros oito meses de vida, também foram estudadas. RESULTADOS: Foram estudados 58 pares mãe-filho (a média de idade das mães foi de 22,1 anos). A maioria (86,2 por cento) das mães residia em áreas urbanas e tinham até 8 anos de escolaridade (51,7 por cento). O diagnóstico foi feito após o nascimento para 19 (32,8 por cento) crianças; 34 (58,6 por cento) mulheres receberam algum tipo de tratamento durante a gravidez. A maioria (72,4 por cento) das crianças não apresentou alterações clínicas ao nascimento. Os principais achados foram oftalmológicos: 20 (34,5 por cento) crianças com retinocoroidite, 17 (29,3 por cento) com estrabismo e 7 (12,1 por cento) com nistagmo. Das crianças com retinocoroidite, 9 apresentaram visão subnormal. Calcificações intracranianas estiveram presentes em 10 (32,3 por cento) das 31 crianças que realizaram toxoplasmose congênita de segmento cefálico e 9 (42,9 por cento) crianças apresentaram atraso do desenvolvimento psicomotor. CONCLUSÕES: Os resultados mostram uma situação crítica. Protocolos para acompanhamento de gestantes e seus filhos devem ser criados para melhorar o atendimento médico e minimizar sequelas.

Abordagem diagnóstica e terapêutica da toxoplasmose em gestantes e as repercussões no recém-nascido / Diagnostic and therapeutic management of toxoplasmosis in pregnancy and the effect in the newborn

OBJETIVO:Avaliar a abordagem diagnóstica e terapêutica da toxoplasmose de gestantes que apresentaram IgM positiva para a doença e o acompanhamento de seus filhos em um hospital público no Rio de Janeiro, RJ. MÉTODOS: Estudo transversal retrospectivo de 2003 a 2006, realizado por meio da análise dos prontuários de 98 gestantes com sorologia IgM positiva para toxoplasmose e seus filhos (99 crianças). O seguimento das crianças com e sem infecção congênita foram analisados, assim como a apresentação clínica daquelas com infecção congênita e os testes diagnósticos utilizados para identificar a infecção pelo Toxoplasma gondii durante a gestação. RESULTADOS: O diagnóstico sorológico foi realizado em 76 pacientes no segundo e terceiro trimestre gestacional. Em 36 gestantes, a determinação dos níveis séricos de IgM foi o único teste diagnóstico realizado para infecção pelo toxoplasma. Em 49 gestantes, os índices de IgM, pela técnica ELFA, foram baixos. O teste de avidez de IgG foi realizado em 62 gestantes e somente 13 o realizaram no primeiro trimestre gestacional. O tratamento específico para toxoplasmose foi empregado em 93 gestantes. A taxa de transmissão vertical foi de 4 por cento. Manifestações clínicas de toxoplasmose congênita foram encontradas em todas as crianças infectadas. Todas as crianças não infectadas apresentaram declínio de IgG específica para toxoplasmose ao longo do acompanhamento ambulatorial; a idade média de IgG comprovadamente negativa nessas crianças foi de 5,4 meses. CONCLUSÕES: Os resultados sugerem que uma sorologia positiva para IgM, como um único marcador sorológico para detectar infecção recente, tem um valor limitado.

OBJECTIVE: To analyze the diagnostic and therapeutic approach of pregnant women with positive IgM test for toxoplasmosis and the follow-up of their children in a public hospital of Rio de Janeiro, Brazil. METHODS: This cross-sectional retrospective study from 2003 to 2006 enrolled 98 pregnant women with positive IgM test for toxoplasmosis and 99 children. The follow-up of the children with or without congenital infection was reviewed, as well as the clinical presentation of those with congenital infection and the laboratory tests used to diagnose the infection by Toxoplasma gondii during pregnancy. RESULTS: Toxoplasmosis was diagnosed in the second and third trimesters of pregnancy in 76 patients. In 36 pregnant women, determination of the serum levels of IgM was the only laboratory method used to diagnose the infection. Low IgM levels analyzed by ELFA were detected in 49 pregnant women. IgG avidity test was performed in 62 patients and in 13 percent of them the exam was carried out during the first trimester of pregnancy. Specific treatment for toxoplasmosis was applied in 93 women. Vertical transmission rate was 4 percent. Clinical manifestation of congenital toxoplasmosis was found in all infected children. All non-infected children showed a decrease in IgG serum levels for toxoplasmosis during the follow-up. The mean age for negativation of IgG serum levels in these children was 5.4 months. CONCLUSIONS: Our results suggest that the use of a positive IgM test to toxoplasmosis as the only antibody marker to detect recent infection has a limited value.

Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis

Clinical trials comparing different drug regimens and strategies for the treatment of congenital toxoplasmosis and its clinical manifestations in the liveborn child in different clinical settings should aim at formally evaluating the net benefit of existing treatments and at developing new therapeutic options. Currently, there is no ideal drug for congenital toxoplasmosis; future research should focus on the screening of new active drugs and on their pre-clinical and early clinical development, with a focus on pharmacokinetic/dynamic studies and teratogenicity. For the prenatal treatment of congenital toxoplasmosis, a trial comparing spiramycine to pyrimethamine-sulphadiazine and placebo would allow a formal estimation of the effect of both drugs in infected pregnant women. In newborn children, the net benefit of pyrimethamine-sulphadiazine should also be formally assessed. These trials will be implemented in settings where prenatal screening for Toxoplasma gondii is currently implemented. Trials should be carefully designed to allow for translation to other settings and modelling tools like cost-effectiveness analysis should be used to provide clinicians and founders with the best available evidence to establish recommendations.

Treatment for congenital toxoplasmosis: finding out what works

Evidence for the effectiveness of prenatal or postnatal treatment for congenital toxoplasmosis will be critical to guide policy about prenatal and neonatal screening over the next 10 years, let alone the next 100. Randomised controlled trials are needed to address questions about treatment effectiveness, although cohort studies are also needed to provide information on prognosis, especially disability. Nowhere are such studies needed more than in South America where congenital toxoplasmosis is a major public health problem.

When are we going to celebrate the centenary of the discovery of efficient treatment for congenital toxoplasmosis?

In 2008, we have celebrated the centenary of the discovery of Toxoplasma gondii.Although this ubiquitous protozoan can generate devastating damage in foetuses and newborns, its treatment is the only field in which we have made little progress, despite a huge body of research, and has not yet been validated. Pregnant women who seroconvert are generally given spiramycine in order to reduce the risk of vertical transmission. However, to date, we have no evidence of the efficacy of this treatment because no randomized controlled trials have as yet been conducted. When foetal contamination is demonstrated, pyrimethamine, in association with sulfadoxine or sulfadiazine, is normally prescribed, but the effectiveness of this treatment remains to be shown. With regard to postnatal treatment, opinions vary considerably in terms of drugs, regimens and length of therapy. Similarly, we do not have clear evidence to support routine antibiotic treatment of acute ocular toxoplasmosis. We must be aware that pregnant women and newborns are currently being given empirically potentially toxic drugs that have no proven benefit. We must make progress in this field through well-designed collaborative studies and by drawing the attention of policy makers to this disastrous and unsustainable situation.

Why prevent, diagnose and treat congenital toxoplasmosis?

Evidence that prevention, diagnosis and treatment of toxoplasmosis is beneficial developed as follows: anti-parasitic agents abrogate Toxoplasma gondiitachyzoite growth, preventing destruction of infected, cultured, mammalian cells and cure active infections in experimental animals, including primates. They treat active infections in persons who are immune-compromised, limit destruction of retina by replicating parasites and thereby treat ocular toxoplasmosis and treat active infection in the fetus and infant. Outcomes of untreated congenital toxoplasmosis include adverse ocular and neurologic sequelae described in different countries and decades. Better outcomes are associated with treatment of infected infants throughout their first year of life. Shorter intervals between diagnosis and treatment in utero improve outcomes. A French approach for diagnosis and treatment of congenital toxoplasmosis in the fetus and infant can prevent toxoplasmosis and limit adverse sequelae. In addition, new data demonstrate that this French approach results in favorable outcomes with some early gestation infections. A standardized approach to diagnosis and treatment during gestation has not yet been applied generally in the USA. Nonetheless, a small, similar experience confirms that this French approach is feasible, safe, and results in favorable outcomes in the National Collaborative Chicago-based Congenital Toxoplasmosis Study cohort. Prompt diagnosis, prevention and treatment reduce adverse sequelae of congenital toxoplasmosis.

Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis

The aim of this study was to determine the incidence of congenital toxoplasmosis (CT) and to assess the performances of prenatal and neonatal diagnoses. From 1994-2005, in Toulouse University Hospital, France, amniocentesis was performed on 352 pregnant women who were infected during pregnancy. All women were treated with spiramycin and pyrimethamine-sulfadoxine when prenatal diagnosis was positive. Among the 275 foetuses with follow-up, 66 (24 percent) were infected. The transmission rates of Toxoplasma gondii were 7 percent, 24 percent and 59 percent in the first, second and third trimesters, respectively. The sensitivity and specificity of PCR on amniotic fluid (AF) were 91 percent and 99.5 percent, respectively. One case was diagnosed by mouse inoculation with AF and six cases were diagnosed by neonatal or postnatal screening. The sensitivity and specificity of PCR on placentas were 52 percent and 99 percent, respectively. The sensitivity of tests for the detection of specific IgA and IgM in cord blood was 53 percent and 64 percent, respectively, and specificity values were 91 percent and 92 percent. In conclusion, PCR performed on AF had the highest levels of sensitivity and specificity for the diagnosis of CT. This permits an early diagnosis of most cases and should be recommended.

Congenital toxoplasmosis infection in an infant born to an HIV-1-infected mother

We report the occurrence of congenital toxoplasmosis in an infant born to an HIV infected mother who had high anti-toxoplasma IgG and negative IgM at nine weeks of gestation. We briefly review available literature and discuss the possible mechanisms of transmission of congenital toxoplasmosis among HIV infected pregnant women.

Evaluación del tratamiento de la toxoplasmosis gestacional en una cohorte colombiana / Evaluation of prenatal treatmen for toxoplasmosis in cohort Colombian

Objetivo. Determinar la utilidad del tratamiento de la toxoplasmosis in útero, en términos del desenlace clínico de los niños durante el primer año de vida. Diseño. Estudio de cohorte prospectivo con seguimiento y evaluación clínica y de laboratorio en niños hasta el primer año de edad. Lugar. Consulta de toxoplasmosis, tercer nivel de referencia en el centro de salud de la Universidad del Quindío. Población. Se estudiaron 38 niños que fueron reclutados en los programas de tamizaje prenatal, programas de tamizaje neonatal y niños que acudieron para diagnóstico neonatal. Mediciones. Medición de anticuerpos anti-Toxoplasma IgG mediante ELISA, IgM e IgA por ISAGA y Western blot. Oftalmoscopia directa por oftalmólogos y resultados de ecografía transfontanelar. Resultados. Se encontraron 26 niños infectados de los 38 estudiados. La transmisión entre madres tratadas ocurrió en 9 de 18 casos (50 por ciento), mientras que en madres no tratadas fue de 17 de 20 (85 por ciento) pero esto estuvo ligado al tiempo de gestación en que se estimó que había ocurrido la infección (OR ajustada de 0,3, IC95 por ciento 0,01-5,5, p =0.07). se encontró una reducción en síntomas en el recién nacido que no alcanzó a ser estadísticamente significativa (OR para síntomas en niños tratados: 0,25, IC95 por ciento 0,03 – 2; p de Fisher = 0,13). Conclusiones. En este grupo de niños colombianos con toxoplasmosis congénita se encuentran los mismos resultados reportados en series con número mayor de casos en Francia. Se espera que el aporte de esta serie al proyecto SYROCOT permita definir si existe un efecto significativo que, aun en caso de que lo haya, no sería muy grande. Esto justifica la búsqueda de medicamentos para esta infección que sean más eficaces

Toxoplasmose congênita: orientação prática sobre prevenção e tratamento / Congenital toxoplasmosis: treatment and prevention guideline

A toxoplasmose, parasitose prevalente em todo o mundo, quando adquirida durante a gestação pode ser transmitida ao feto e causar, dentre outros problemas, atraso no desenvolvimento neuropsicomotor, estrabismo, déficit visual e perdas auditivas. A prevenção da transmissão vertical deve ser iniciada antes da con- cepção ou o mais precocemente possível durante o pré-natal. A identificação de gestantes susceptíveis (soronegativas) deve ser acompanhada de orientações escritas e verbais sobre as formas de aquisição da infecção (profilaxia primária) e, se bem realizada, tem se mostrado eficaz. As mulheres com contato prévio com o parasito, antes da gestação, se imunocompetentes, apresentam muito baixo risco de infectar o concepto. Mas, as gestantes agudamente infectadas devem ser identificadas precocemente para instituição de terapêutica adequada (profilaxia secundária) com o objetivo de evitar a infecção ou diminuir as suas conseqüências para o feto. Considerando-se que a infecção adquirida, assim como a congênita, são geralmente assintomáticas, devemos utilizar a triagem sorológica da mãe e, posteriormente da criança suspeita, para diagnosticar e tratar esses casos. Os autores se pro- põem a apresentar uma orientação prática para abordagem do binômio mãe/filho suspeitos de toxoplasmose, com base nos conhecimentos disponíveis no momento e de acordo com o protocolo utilizado no Serviço de Doenças Infecciosas e Parasitárias, setor de Infectologia Pediátrica, do Hospital das Clínicas da Universidade Federal de Minas Gerais.

The toxoplasmosis, a prevalent parasitosis throughout the world, when acquired during pregnancy can be transmítted to the fetus and cause, among other problems, delay in the neuropsychomotor development, strabismus and visual and hearing impairment. The vertical transmission prevention must be initiated before conception or as early as possible in the prenatal assessment. The identification of susceptible pregnant woman (nega tive blood test) must be accompanied by written and verbal orientation about how the disease can be acquired (primary prophylaxis) and, if well per- formed, has showed good efficacy. Women with previous contact with the parasite, before pregnancy, if imunecompetents, show a very low risk of infecting the child. But, the pregnant women acutely infected must be identified early for the implementation of adequa te therapeutics (secondary prophylaxis) aiming to avoid infection ar at least decrease its consequence to the fetus. Considering that the acquired infection as well as the congenital are usually assymptomatic, we should use the mother's serological screening and, afterwards the child's to diagnose and treat these cases. The authors intend to show a public guideline in the assessment of the mother/child suspects of being infected with toxoplasmosis, based in the current available knowledge and according to the protocol used in the Serviço de Doenças Infecciosas e Parasitárias, Setor de Infectologia Pediátrica, Hospital das Clínicas da Universidade Federal de Minas Gerais.

Hallazgos ultrasonografico prenatales atipicos asociados a toxoplasmosis connatal

Se presenta un caso clínico con diagnóstico final de toxoplasmosis connatal, destacando la pesquisa de hallazgos ultrasonográficos de rara ocurrencia.Se presenta la experiencia del Hospital Clínico de la Universidad de Chile, proponiendo una aproximación actualizada al diagnóstico y tratamiento de la toxoplasmosis durante el embarazo.

Características clínicas, curso evolutivo y complicaciones en toxoplasmosis ocular activa consulta externa Centro Nacional de Oftalmología Managua, 2000 y 2001 / Clinical characteristics, evolutionary course and complications in toxoplasmosis ocular active external consultation, National Center of Oftalmology. Managua 2000- 2001

Se realizo un estudio tipo observacional descriptivo, con el objetivo de determinar las características clínicas, el curso evolutivo y las complicaciones de los casos de Toxoplasmosis Ocular en su forma activa, atendidos en la consulta externa del Centro Nacional de Oftalmología durante los años 2000 y 2001. se revisaron un total de 64 expedientes clínicos con dicho diagnóstico, los cuales fueron obtenidos de las hojas de consulta diaria del servicio de polo posterior y recolectada dicha información a través de una ficha elaborada para tal fin. Los datos fueron procesados en el programa EPI- INFO versión 6.04. Despues de analizar los datos se obtuvieron los principales resultados: La patología se presento mayormente en el grupo etareo de 10 a 29 años (78.4 porciento) y un poco mas frecuente entre el sexo femenino (54.7 porciento). Del total de casos consignados en mas de la mitad (57.6 porciento) se presento como una uveitis posterior pura y en un 42.4 porciento como panuveitis. El diagnóstico fue realizado en un 55 porciento de forma clínica y de forma mixta (clínico y de laboratorio), en un 40 porciento. El foco infeccioso se ubico en la periferia de la retina en un 71 porciento y de forma central en un 29 porciento. En casi la mitad de los casos (48 porciento), la agudeza visual se presento con daño severo a momento del ingreso. El tratamiento inicial instaurado fue en su mayoría (70 porciento), el esquema standard de Pirimetamina-Trimetropin Sulfa- Esteroide Oral, el cual se demostró que continua siendo efectivo para el control de la enfermedad activa, ya que despues de finalizado el tratamiento inicial, el 98 porciento de los focos estaban inactivos. La agudeza visual final en la mitad de los casos fue registrada como daño leve, después de terminar el tratamiento. El 45 porciento de casos presento algún tipo de complicación ocular, siendo las mas frecuente la cicatriz macular (16 porciento)...

Tratamiento de la toxoplasmosis: esquemas para la forma congénita y en el inmunosuprimido / Toxoplasmosis therapy: schedule for congenital form in the immunosupressed patient

La combinación de Pirimetamina-Sulfadiazina ha demostrado ser el antibiótico más efectivo para el tratamiento de la toxoplasmosis, sin embargo, su utilización durante el embarazo se ve limitada por sus efectos teratogénicos si se administra en el primer trimestre. La base farmacológica que explica su acción terapéutica consiste en la eliminación de dos pasos en la via biosintética que conduce a la formación del ácido folínico. El toxoplasma no puede utilizar el ácido fólico ni el folínico del husped para la síntesis de acidos nucleicos por lo tanto debe fabricárselos a partir del acido paraaminobenzoico (PABA). La Pirimetamina y las sulfamidas son activas independientemente para inhibir este paso y juntas son excelente ejemplo de potencialización farmacológica.